Latest Tyrosine kinase inhibitors Stories

SINGAPORE, June 9 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF). These two multi-center, single-arm, open-label studies are designed to evaluate the efficacy and safety of SB1518 in patients with MF. Based on the clinical data derived from the Phase 1 trial,...

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The results of the ZETA study were presented today at the American Society of Clinical...

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapyDasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology June 5,...

Phase III clinical trials show improved responses over standard of careTwo drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine.Separate international phase III clinical trials compared high-quality remissions after one year of treatment between the standard-of-care drug imatinib, also...

Combination of targeted agent, chemotherapy improves progression-free survival; therapy inhibits both VEGFR and EGFRWhen combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.The findings, published in the Lancet Oncology, mark the first clinical benefit of a...

EAST HANOVER, N.J., June 4 /PRNewswire/ -- Novartis announced today 18-month results (median follow-up) showing that Tasigna® (nilotinib) capsules significantly surpass the efficacy of Gleevec® (imatinib mesylate) tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1). To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/novartis/44499/ This...

SUNNYVALE, Calif., May 20 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the abstract it submitted for the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010 in Chicago, IL was released by ASCO today. The abstract was selected for an oral presentation. In the abstract the company reported efficacy results on 19 evaluable patients out of 22 patients in the first three cohorts. Each of these patients had received a minimum of...

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) "Pfizer Oncology is committed to applying discoveries from cancer...

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.Chronic myelogenous leukemia (CML) is a deadly form of leukemia that is associated with chromosome...

2nd European Lung Cancer ConferenceTesting for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.Erlotinib is one of a class of drugs that specifically inhibits an important...